(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 July 2014 (03.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/102692 A1

(51) International Patent Classification:
A61K 35/74 (2006.01) *A61P 3/10* (2006.01)
A61P 9/10 (2006.01) *A61P 39/06* (2006.01)

(21) International Application Number:
PCT/IB2013/061216

(22) International Filing Date:
20 December 2013 (20.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1223370.6 24 December 2012 (24.12.2012) GB

(71) Applicant: **UNIVERSITY OF TARTU** [EE/EE]; Ülikooli 18, EE-50090 Tartu (EE).

(72) Inventors: **KULLISAAR, Tiiu**; Ülikooli 18, EE-50090 Tartu (EE). **ZILMER, Mihkel**; Ülikooli 18, EE-50090 Tartu (EE). **SMIDT, Imbi**; Ülikooli 18, EE-50090 Tartu (EE). **ZILMER, Kersti**; Ülikooli 18, EE-50090 Tartu (EE). **MIKELSAAR, Marika**; Ülikooli 18, EE-50090 Tartu (EE). **HÜTT, Pirje**; Ülikooli 18, EE-50090 Tartu (EE).

(74) Agents: **GOODFELLOW, Hugh Robin** et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: METHOD OF TREATMENT USING *LACTOBACILLUS FERMENTUM* ME-3




Figure 1

(57) Abstract: The invention provides a composition comprising *Lactobacillus fermentum* ME-3 strain DSM 14241 for use in preventing, alleviating the symptoms of or treating, alone or as an adjuvant component,a metabolic syndrome related disorder selected from prediabetes, type 2 diabetes and cardiovascular disease. The effect may be achieved by simultaneously:decreasing the level of glycated haemoglobin HbA1c, decreasing or preventing low-grade inflammation on a cellular level and increasing the level of adiponectin.

WO 2014/102692 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*